

**Supplementary Table 1. Comparison in outcomes between our cohort and other studies.**

	Comparison in outcomes rates		
	Our cohort	Other study	P-value*
<b>GWTG study (Srivastava et al)</b>			
In-hospital mortality†	81/207 (39.1%)	1895/39479 (4.8%)	<0.001
Discharge mRS 0-2†	34/191 (17.8%)	10751/27218 (39.5%)	<0.001
sICH in IV tPA patients†	3/39 (7.7%)	160/4444 (3.6%)	0.168
<b>MR CLEAN study (Berkhemer et al)</b>			
7-day mortality‡	14/37 (37.8%)	27/233 (11.6%)	<0.001
7-day mortality§	27/46 (58.7%)	33/267 (12.4%)	<0.001
sICH‡	6/37 (16.2%)	18/233 (7.7%)	0.092
sICH§	4/46 (8.7%)	17/267 (6.4%)	0.527
<b>Global COVID-19 Stroke Registry (Ntaios et al)</b>			
In-hospital mortality#	81/207 (39.1%)	48/174 (27.6%)	0.018
Median [IQR] discharge mRS#	N=191; 5.00 [3.00]	N=125; 4.00 [4.00]	

GWTG: Get With The Guidelines–Stroke; mRS: Modified Rankin Scale; IV tPA: Intravenous tissue plasminogen activator; sICH, Symptomatic intracranial haemorrhage; MR CLEAN: Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands.

\*Chi-square or Fisher exact test were used as appropriate; † Our cohort vs. their non-COVID-19 acute ischemic stroke; ‡ Our thrombectomy cases vs. their interventional arm; § Our non- thrombectomy large vessel occlusion cases vs. their control arm; # Our cohort vs. their COVID-19 acute ischemic stroke.